MIKKELSEN JAN MOLLER

PrivateCIK: 1180765
Location

HELLERUP, G7

MIKKELSEN JAN MOLLER enters ASCENDIS PHARMA A/S with 453.40K shares plus derivative instruments

Holding both equity and derivatives at entry signals strong long-term conviction in the company.

Direct Indirect Derivatives
InsiderMIKKELSEN JAN MOLLERCIK 1180765
IssuerASCENDIS PHARMA A/SCIK 1612042
Director
Since Mar 2026
453.40K
Baseline shares
85% direct
384.93K
Direct ownership
1 position
759.22K
Derivative underlying
8 instruments
2
Security positions
68.47K indirect
Non-Derivative Holdings2

Ordinary Shares

Direct
Shares owned384.93K

Ordinary Shares

Indirect
Shares owned68.47K
Total
384.93K direct·68.47K indirect453.40K
Derivative Holdings8

Warrants

Direct
Underlying security
Ordinary Shares

Underlying shares

120K

Shares owned

N/A

Exercise price

108

Expiration

Exercise window

Restricted Stock Units

Direct
Underlying security
Ordinary Shares

Underlying shares

23.83K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Warrants

Direct
Underlying security
Ordinary Shares

Underlying shares

69.47K

Shares owned

N/A

Exercise price

139.65

Expiration

Exercise window

Restricted Stock Units

Direct
Underlying security
Ordinary Shares

Underlying shares

28.95K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Warrants

Direct
Underlying security
Ordinary Shares

Underlying shares

200K

Shares owned

N/A

Exercise price

62.17

Expiration

Exercise window

Restricted Stock Units

Direct
Underlying security
Ordinary Shares

Underlying shares

15.82K

Shares owned

N/A

Exercise price

Expiration

Exercise window

Warrants

Direct
Underlying security
Ordinary Shares

Underlying shares

200K

Shares owned

N/A

Exercise price

37.18

Expiration

Exercise window

Warrants

Direct
Underlying security
Ordinary Shares

Underlying shares

101.14K

Shares owned

N/A

Exercise price

176.28

Expiration

Exercise window

Total

Underlying

759.22K

Owned

0.00

MIKKELSEN JAN MOLLER — Initial Ownership Disclosure (Form 3) Filed Mar 18, 2026 | Finecho